Enfu Hui[Author] - Search Results

Year	Number of Results
2004	2
2005	1
2006	2
2008	4
2009	2
2010	1
2011	1
2014	2
2015	1
2016	1
2017	2
2018	1
2019	4
2020	3
2021	1
2022	2
2023	5
2024	0

1

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, Vale RD. Hui E, et al. Science. 2017 Mar 31;355(6332):1428-1433. doi: 10.1126/science.aaf1292. Epub 2017 Mar 9. Science. 2017. PMID: 28280247 Free PMC article.

2

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8⁺ T cell responses.

Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O'Gorman WE, Wu TD, Mittman S, Cubas R, Comps-Agrar L, Fulzele A, Bennett EJ, Grogan JL, Hui E, Chiang EY, Mellman I. Banta KL, et al. Among authors: hui e. Immunity. 2022 Mar 8;55(3):512-526.e9. doi: 10.1016/j.immuni.2022.02.005. Immunity. 2022. PMID: 35263569 Free PMC article.

3

Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy.

Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, Huang M, Meng L, He X, Zhu H, Gao S, Zhang N, Jing R, Sun J, Wang H, Hui E, Wong CC, Xu C. Wu W, et al. Among authors: hui e. Cell. 2020 Aug 20;182(4):855-871.e23. doi: 10.1016/j.cell.2020.07.018. Epub 2020 Jul 29. Cell. 2020. PMID: 32730808 Free article.

4

Phase separation of signaling molecules promotes T cell receptor signal transduction.

Su X, Ditlev JA, Hui E, Xing W, Banjade S, Okrut J, King DS, Taunton J, Rosen MK, Vale RD. Su X, et al. Among authors: hui e. Science. 2016 Apr 29;352(6285):595-9. doi: 10.1126/science.aad9964. Epub 2016 Apr 7. Science. 2016. PMID: 27056844 Free PMC article.

5

cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8⁺ T cell function and anti-tumor immunity.

Zhao Y, Caron C, Chan YY, Lee CK, Xu X, Zhang J, Masubuchi T, Wu C, Bui JD, Hui E. Zhao Y, et al. Among authors: hui e. Immunity. 2023 Jun 13;56(6):1187-1203.e12. doi: 10.1016/j.immuni.2023.04.005. Epub 2023 May 8. Immunity. 2023. PMID: 37160118

6

Immune checkpoint inhibitors.

Hui E. Hui E. J Cell Biol. 2019 Mar 4;218(3):740-741. doi: 10.1083/jcb.201810035. Epub 2019 Feb 13. J Cell Biol. 2019. PMID: 30760493 Free PMC article. Review.

7

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.

Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, Huang Z, Xiao C, Bonorino C, Lu LF, Bui JD, Hui E. Zhao Y, et al. Among authors: hui e. Immunity. 2019 Dec 17;51(6):1059-1073.e9. doi: 10.1016/j.immuni.2019.11.003. Epub 2019 Nov 19. Immunity. 2019. PMID: 31757674 Free PMC article.

8

CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity.

Tang Z, Zhong MC, Qian J, Galindo CC, Davidson D, Li J, Zhao Y, Hui E, Veillette A. Tang Z, et al. Among authors: hui e. Nat Immunol. 2023 Dec;24(12):2032-2041. doi: 10.1038/s41590-023-01671-2. Epub 2023 Nov 9. Nat Immunol. 2023. PMID: 37945822

9

Cis Interactions of Membrane Receptors and Ligands.

Hui E. Hui E. Annu Rev Cell Dev Biol. 2023 Oct 16;39:391-408. doi: 10.1146/annurev-cellbio-120420-103941. Epub 2023 Jun 20. Annu Rev Cell Dev Biol. 2023. PMID: 37339682 Free article. Review.

10

Understanding T cell signaling using membrane reconstitution.

Hui E. Hui E. Immunol Rev. 2019 Sep;291(1):44-56. doi: 10.1111/imr.12767. Immunol Rev. 2019. PMID: 31402497 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

34 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year